REVENUE AND DEFERRED REVENUE (Tables)

3 Months Ended

Mar. 31, 2025

Schedule of percentages of deferred revenue by year

As of March 31, 2025, the Company expects to recognize approximately the following percentages of deferred revenue by year:

	Revenue
Year:	Recognition
Remainder of 2025	87	%
2026	13	%
Total	100	%

Schedule of revenue generated in geographic regions for years indicated

	Revenues by Geography
	Three Months Ended March 31,
	2025				2024
			% of				% of
	Amount		Revenues		Amount		Revenues
	(in thousands, except percentages)
U.S.	$	31,483	98	%	$	16,793	96	%
International		492	2	%		624	4	%
Total revenues	$	31,975	100	%	$	17,417	100	%

U.S.

Schedule of revenue generated in product category for years indicated

	U.S. Revenues by Product Category
	Three Months Ended March 31,
	2025				2024
			% of				% of
	Amount		Revenues		Amount		Revenues
	(in thousands, except percentages)
NeuroStar Advanced Therapy System	$	2,846	9	%	$	3,310	20	%
Treatment sessions		9,612	31	%		12,988	77	%
Clinic revenue		18,659	59	%		—	—	%
Other		366	1	%		495	3	%
Total U.S. revenues	$	31,483	100	%	$	16,793	100	%

International

Schedule of revenue generated in product category for years indicated

	International Revenues by Product Category
	Three Months Ended March 31,
	2025				2024
			% of				% of
	Amount		Revenues		Amount		Revenues
	(in thousands, except percentages)
NeuroStar Advanced Therapy System	$	164	33	%	$	258	41	%
Treatment sessions		150	31	%		172	28	%
Other		178	36	%		194	31	%
Total international revenues	$	492	100	%	$	624	100	%